COVIDRIVE

A public-private partnership for the estimation of brand-specific COVID-19 vaccine effectiveness in Europe 

What is COVIDRIVE?

COVIDRIVE is a public-private partnership launched in June 2021 to address the joint need to monitor COVID-19 vaccination programmes for public health institutes in Europe and to assess brand-specific COVID-19 vaccine effectiveness (CVE) for the companies as part of their regulatory obligations. To tackle the COVID-19 public health crisis, the European Medicines Agency (EMA) has recommended to make use of existing efforts and encourage a common approach to assess COVID-19 vaccines in real life settings.

COVIDRIVE is performing brand-specific studies through a multi-stakeholder’s public-private European collaborative platform. Our first COVID-19 vaccine effectiveness study started in September 2021.
COVIDRIVE is leveraging an existing vaccine effectiveness platform (DRIVE) which provides yearly brand-specific influenza vaccine effectiveness (IVE) estimates to the EMA.

COVIDRIVE consortium is open to new partners (public health institutes, pharmaceutical companies, small-medium enterprises, academia…) and new study sites to be part of our European-wide network.

VISION AND MISSION

JOINING FORCES TOWARDS A BETTER UNDERSTANDING OF VACCINES AND PREVENTION OF INFECTIOUS DISEASES

To jointly develop methodological and technical resources to undertake CVE vaccine studies in Europe

To set up a research network of Study Contributors across Europe and be able to conduct multi-centre infectious disease and vaccine studies representative of the continent

To leverage established public health capacities and optimize Health Care Practitioner resources in data collection

To build a sustainable partnership by establishing and maintaining a rich scientific community, central data sharing & analysis platform, supporting study documents and regulatory pathway processes

Scope

The partnership intends to conduct multiple COVID-19 vaccine effectiveness (CVE) studies which fall under the following scope:
  • overall and/or vaccine type and/or brand-specific,
  • severe, mild and/or asymptomatic COVID-19 disease outcomes,
  • hospital and/or primary care setting(s),
  • population(s) targeted by the vaccination and/or population(s) of special interest,
  • mid-term and/or long-term CVE,
  • CVE by genetic variants,
  • CVE by time since vaccination and/or by calendar time, and
  • CVE by disease level of severity.

    • PARTNERS

    NON INDUSTRY PARTNERS
    Fisabio Completo_inglés
    P95_LOGO_RGB
    thl-logo-en

    FISABIO (Spain)

    Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

    P95 (Belgium)

    Excellence in pharmacovigilance and Epidemiology 

    THL (Finland)

    Finnish Institute for Health and Welfare

    VACCINE COMPANIES

    AstraZeneca
    (United Kingdom)

    CureVac
    (Germany)

    GlaxoSmith Kline
    (Belgium)

    Janssen
    (Belgium)

    Moderna
    (United States)

    Novavax
    (United States)

    Sanofi Pasteur
    (France)

    Valneva
    (France)